Blood inflammation marker changes after starting steroids for giant cell arteritis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tracks how quickly your C-reactive protein (CRP) level, a marker of inflammation, drops after you start taking steroids (glucocorticoids) for giant cell arteritis. The goal is to find better ways to monitor treatment response in this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been newly diagnosed with giant cell arteritis (inflammation of blood vessels).
- You are admitted to the hospital's internal medicine department for treatment.
- You are not planning to use steroid-sparing medications (other drugs that help lower steroid dose) during the hospital stay.
- Your kidney function is normal (no kidney disease).
- You do not have vision loss from the condition.
- You are not taking immunosuppressants or biologics, and you do not have HIV or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This trial compares two different lengths of steroid treatment for giant cell arteritis, an inflammatory blood vessel disease. Participants receive the medication tocilizumab along with either 8 weeks or 26 weeks of prednisone, to see if a shorter course is just as safe and effective.
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This trial is for people newly diagnosed with giant cell arteritis (GCA) who have a 'halo' sign on their temporal artery ultrasound. It will study how quickly the halo disappears after starting steroid treatment, helping doctors understand the best way to use steroids for this condition.
This study looks at immune cells called B-cells in people with giant cell arteritis (a condition causing inflammation in blood vessels) and other immune disorders, to see if targeting these cells could be a new treatment. It involves imaging and blood tests.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.